Antitrust & Competition Life Sciences Quarterly Update - Q3 2023 | Goodwin

The FTC’s Amgen/Horizon Lawsuit Ends With a Whimper - We covered the FTC’s investigation into (and litigation challenging) Amgen’s $28.3 billion acquisition of rare...

Related Keywords

United States ,Linam Khan ,Albert Bourla ,Abbvie Allergan ,Life Sciences Leaders ,Partnership To Promote Benefits Of Pro ,Novartis ,Capitol Forum ,Amgen ,Pfizer ,Senate Subcommittee On ,Big Pharma ,Horizon Lawsuit Ends With ,Horizon Therapeutics ,Litmus Test ,Cantor Fitzgerald Global Healthcare Conference ,Big Tech ,Still Worried About ,Antitrust Enforcement ,Draft Merger Guidelines Spur ,Life Science Industry ,Draft Revised Merger Guidelines ,Science Ecosystem ,Draft Merger ,Draft Merger Guidelines ,Giant Amgen ,Estate Challenges ,Horizon Therapeutics Acquisition ,Restrict Future Acquisitions ,Pursue Anticompetitive Mergers ,Senate Subcommittee ,Federal Trade Commission Before ,United States Senate Committee ,Judiciary Subcommittee ,Competition Policy ,Consumer Rights ,Antitrust Laws ,Sciences Leaders ,Advocates Launch New Partnership ,Promote Benefits ,Pro Innovation Mergers ,